The COVID-19 vaccine being produced by Pfizer and BioNTech has now proved to be 95% effective in preventing coronavirus and the firms have said that is has met the safety criteria needed for emergency authorisation.
Pfizer and BioNTech have also said that their plan is to submit the vaccine to the US regulator for emergency-use approval, within days, before sharing it with others around the world.
Final efficacy analysis of the jab showed 95% were protected from the virus within 28 days of the first dose – up from when results of Phase 3 trials were shared last week. The vaccine also proved to be 94% effective among adults over the age of 65 – who are widely considered as being more vulnerable.
“No serious safety concerns” were reported in the analysis, with only 2% of the 43,000 involved having reported a headache and 3.7% reporting fatigue, the companies said.
Pfizer is one of the companies with which the European Commission has agreements in place, to ensure a fair and proportionate distribution, among all the EU member states, which includes Malta.